MEDI3506

Phase 3Small molecule

AstraZeneca

MEDI3506 is one of 60 small molecule programs targeting Lupus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LupusActive, not recruiting

Atopic DermatitisActive, not recruiting

AsthmaActive, not recruiting

LupusPhase 3

Active, not recruiting

Atopic DermatitisPhase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

46 2

Xolair

Roche

Preclinical

25 3

MEDI3506

AstraZeneca

Phase 3

1 4

Cinqair

Teva

Preclinical

13 5

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 6

Asmanex

Novartis

Preclinical

5 7

Celexa

AbbVie

Preclinical

1 8

Spiriva

Boehringer Ingelheim

Preclinical

8 9

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 10

Arcoxia

Novartis

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Lupus

NCT04170543

Clinical

Trials by Indication[1]

COPD1 trial

Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03096795·88 enrolled

Atopic Dermatitis1 trial

Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT04212169·148 enrolled

Asthma1 trial

Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT04570657·250 enrolled

Immunogenicity1 trial

Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05070312·39 enrolled

Lupus1 trial

GLOW-1: Efgartigimod in Systemic Lupus

Recruiting· Argenx logo

Argenx·Phase 3·NCT04170543·450 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for MEDI3506. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MEDI3506 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MEDI3506. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

MEDI3506

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

COPD1 trial

Atopic Dermatitis1 trial

Asthma1 trial

Immunogenicity1 trial

Lupus1 trial

References

Drug Info

Quick Facts

Related News